Rapamycin/IL-2 Combination Therapy in Patients With Type 1 Diabetes Augments Tregs yet Transiently Impairs β-Cell Function

Rapamycin/interleukin-2 (IL-2) combination treatment of NOD mice effectively treats autoimmune diabetes. We performed a phase 1 clinical trial to test the safety and immunologic effects of rapamycin/IL-2 combination therapy in type 1 diabetic (T1D) patients. Nine T1D subjects were treated with 2–4 m...

Descripción completa

Detalles Bibliográficos
Autores principales: Long, S. Alice, Rieck, Mary, Sanda, Srinath, Bollyky, Jennifer B., Samuels, Peter L., Goland, Robin, Ahmann, Andrew, Rabinovitch, Alex, Aggarwal, Sudeepta, Phippard, Deborah, Turka, Laurence A., Ehlers, Mario R., Bianchine, Peter J., Boyle, Karen D., Adah, Steven A., Bluestone, Jeffrey A., Buckner, Jane H., Greenbaum, Carla J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Diabetes Association 2012
Materias:
Immunology and Transplantation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3425404/
https://www.ncbi.nlm.nih.gov/pubmed/22721971
http://dx.doi.org/10.2337/db12-0049

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3425404/
https://www.ncbi.nlm.nih.gov/pubmed/22721971
http://dx.doi.org/10.2337/db12-0049

Ejemplares similares